Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 8/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.50 |
| ▸ | TAF1 | P21675 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736393 | 0.90 | SIRT6 (0.52) | AURKAAURKBBRD4LRRK2BRDT | |
| SCHEMBL759232 | 0.86 | BRD4 (0.46) | BRD4LRRK2PTK2 | |
| SCHEMBL758810 | 0.85 | KMT2A (0.43) | LRRK2MCHR1 | |
| SCHEMBL3939908 | 0.83 | POLB (0.47) | AURKAAURKBMCHR1 | |
| SCHEMBL3541959 | 0.83 | POLB (0.47) | AURKAAURKBMCHR1 | |
| SCHEMBL3544241 | 0.83 | ALDH1A1 (0.61) | — | |
| SCHEMBL16972143 | 0.82 | PTPN7 (0.56) | AURKAAURKBBRD4LRRK2BRDT | |
| SCHEMBL9964598 | 0.81 | BRD4 (0.55) | AURKAAURKBBRD4LRRK2BRDT | |
| SCHEMBL738237 | 0.80 | HTR4 (0.53) | AURKAAURKBBRD4LRRK2BRDT | |
| SCHEMBL15082471 | 0.80 | AURKA (0.57) | AURKAAURKBBRD4LRRK2BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202867-B2 | Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-7728134-B2 | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090318457-A1 | Methods of Using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090298840-A1 | Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298840-A1 | Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | CYP3A7, CYP2C8, UGT2B7 | AURKA 2228/4885AURKB 2664/4885BRD4 150/4885 |
| US-20090318457-A1 | Methods of Using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide | CYP3A7, UGT2B7, CYP2C8 | AURKA 2273/4885AURKB 2664/4885BRD4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.